Protein Supplements to Cyclists

H

Haukeland University Hospital

Status

Unknown

Conditions

Reconstitution After Bicycle Intervention

Treatments

Dietary Supplement: Active protein drink

Study type

Interventional

Funder types

Other

Identifiers

NCT03136133
2017/56

Details and patient eligibility

About

To investigate the effect of marine peptide combined with dietary protein on the capacity to recover after exhaustive endurance cycling as measured by exercise capacity and blood glucose homeostasis.

Full description

The current study uses cyclists as test subjects since they represent a physical demanding sport requiring both high endurance capacity and muscle strength. In the recovery phase following exhaustive physical activity there is a need both for rebuilding the muscle energy stores, for muscle repair and for compensatory muscle cell development. Therefore, marine peptide combined with dietary protein will be given in order to examine the capacity to recover after exhaustive endurance cycling.

Enrollment

16 estimated patients

Sex

Male

Ages

40 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Signed informed Consent
  • The subject is a man between 40-50 years
  • The subject has a body mass index (BMI) between 19-29
  • Willing to comply with all study procedures and be available for the length of the study
  • In good general health as judged by the physician at the screening visit

Exclusion criteria

  • The subject has had surgery or trauma with significant blood loss or has donated blood within the last 3 months prior to the screening visit
  • Diabetes type 1 or 2, or persistent high blood sugar levels
  • The subject has tested positive for human immunodeficiency virus (HIV)
  • Hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV)
  • The subject has taken any investigational drugs within 1 month prior to screening
  • Treated with antibiotics within 3 months prior to screening (oral, parenteral or rectal), but not spray or ointment
  • Treated with steroids within 1 month prior to screening (including oral treatment)
  • Treated with medication that effects the intestinal function such as, H2- protonpump inhibitors, diuretics, antiemetics, antidepressants, antacids,

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

16 participants in 2 patient groups, including a placebo group

Active protein drink
Active Comparator group
Description:
Active protein drink
Treatment:
Dietary Supplement: Active protein drink
Placebo drink
Placebo Comparator group
Description:
Placebo drink
Treatment:
Dietary Supplement: Active protein drink

Trial contacts and locations

1

Loading...

Central trial contact

Trygve Hausken, MD; Bente Frisk

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems